At present, FDA-approved AChE inhibitors have shown short-term benefits for improving cognitive symptoms and have no benefits in delaying the progression of AD [9]; an Aβ protofibril-clearing antibody, lecanemab (10 mg/kg of body weight, every two weeks), was shown to reduce cognitive decline by 25% compared with a placebo in an 18-month phase-III trial for mild cognitive impairment or mild dementia caused by AD [14]. This evidence concerns the gene ACHE and Alzheimer disease.